Literature DB >> 21403038

Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort.

Ian H de Boer1, Tessa C Rue, Patricia A Cleary, John M Lachin, Mark E Molitch, Michael W Steffes, Wanjie Sun, Bernard Zinman, John D Brunzell, Neil H White, Ronald P Danis, Matthew D Davis, Dean Hainsworth, Larry D Hubbard, David M Nathan.   

Abstract

BACKGROUND: Microalbuminuria is a common diagnosis in the clinical care of patients with type 1 diabetes mellitus. Long-term outcomes after the development of microalbuminuria are variable.
METHODS: We quantified the incidence of and risk factors for long-term renal outcomes after the development of microalbuminuria in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. The DCCT randomly assigned 1441 persons with type 1 diabetes to intensive or conventional diabetes therapy, and participants were subsequently followed up during the observational EDIC study. During the DCCT/EDIC study, 325 participants developed incident persistent microalbuminuria (albumin excretion rate, ≥30 mg/24 h at 2 consecutive study visits). We assessed their subsequent renal outcomes, including progression to macroalbuminuria (albumin excretion rate, ≥300 mg/24 h at 2 consecutive visits), impaired glomerular filtration rate (estimated glomerular filtration rate, <60 mL/min/1.73 m(2) at 2 consecutive study visits), end-stage renal disease, and regression to normoalbuminuria (albumin excretion rate, <30 mg/24 h at 2 consecutive visits).
RESULTS: The median follow-up period after persistent microalbuminuria diagnosis was 13 years (maximum, 23 years). Ten-year cumulative incidences of progression to macroalbuminuria, impaired glomerular filtration rate, end-stage renal disease, and regression to normoalbuminuria were 28%, 15%, 4%, and 40%, respectively. Albuminuria outcomes were more favorable with intensive diabetes therapy, lower glycated hemoglobin level, absence of retinopathy, female sex, lower blood pressure, and lower concentrations of low-density lipoprotein cholesterol and triglycerides. Lower glycated hemoglobin level, absence of retinopathy, and lower blood pressure were also associated with decreased risk of impaired glomerular filtration rate.
CONCLUSIONS: After the development of persistent microalbuminuria, progression and regression of kidney disease each commonly occur. Intensive glycemic control, lower blood pressure, and a more favorable lipid profile are associated with improved outcomes. ©2011 American Medical Association. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21403038      PMCID: PMC3085024          DOI: 10.1001/archinternmed.2011.16

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  36 in total

1.  Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy.

Authors:  E R Seaquist; F C Goetz; S Rich; J Barbosa
Journal:  N Engl J Med       Date:  1989-05-04       Impact factor: 91.245

2.  Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion.

Authors:  H H Parving; B Oxenbøll; P A Svendsen; J S Christiansen; A R Andersen
Journal:  Acta Endocrinol (Copenh)       Date:  1982-08

3.  Introduction to sample size determination and power analysis for clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1981-06

4.  Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus.

Authors:  K Borch-Johnsen; S Kreiner
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-27

5.  Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes.

Authors:  Bruce A Perkins; Linda H Ficociello; Betsy E Ostrander; Kristen H Silva; Janice Weinberg; James H Warram; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2007-02-28       Impact factor: 10.121

6.  Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group.

Authors: 
Journal:  Kidney Int       Date:  1995-06       Impact factor: 10.612

7.  Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes.

Authors:  C E Mogensen
Journal:  N Engl J Med       Date:  1984-02-09       Impact factor: 91.245

8.  Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study.

Authors:  A R Andersen; J S Christiansen; J K Andersen; S Kreiner; T Deckert
Journal:  Diabetologia       Date:  1983-12       Impact factor: 10.122

9.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

10.  Predictors of microalbuminuria in individuals with IDDM. Pittsburgh Epidemiology of Diabetes Complications Study.

Authors:  B A Coonrod; D Ellis; D J Becker; C H Bunker; S F Kelsey; C E Lloyd; A L Drash; L H Kuller; T J Orchard
Journal:  Diabetes Care       Date:  1993-10       Impact factor: 19.112

View more
  136 in total

Review 1.  Anti-fibrosis therapy and diabetic nephropathy.

Authors:  Anil Karihaloo
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

2.  Coprogression of Cardiovascular Risk Factors in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study.

Authors: 
Journal:  Diabetes Care       Date:  2016-07-19       Impact factor: 19.112

3.  Autoimmunity: Celiac disease in T1DM-the need to look long term.

Authors:  Marian Rewers; George S Eisenbarth
Journal:  Nat Rev Endocrinol       Date:  2011-11-08       Impact factor: 43.330

4.  The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study.

Authors:  Ionut Bebu; Barbara H Braffett; Rodica Pop-Busui; Trevor J Orchard; David M Nathan; John M Lachin
Journal:  Diabetologia       Date:  2017-07-16       Impact factor: 10.122

Review 5.  Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.

Authors:  Ankur Jindal; Mariana Garcia-Touza; Nidhi Jindal; Adam Whaley-Connell; James R Sowers
Journal:  Endocrinol Metab Clin North Am       Date:  2013-08-01       Impact factor: 4.741

6.  Urine clusterin/apolipoprotein J is linked to tubular damage and renal outcomes in patients with type 2 diabetes mellitus.

Authors:  Sang Soo Kim; Sang Heon Song; Jong Ho Kim; Yun Kyung Jeon; Bo Hyun Kim; Min-Cheol Kang; Sung Wan Chun; Soo Hyun Hong; Michelle Chung; Yong Ki Kim; In Joo Kim; Young-Bum Kim
Journal:  Clin Endocrinol (Oxf)       Date:  2017-05-22       Impact factor: 3.478

Review 7.  Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes.

Authors:  Andrzej S Krolewski; Tomohito Gohda; Monika A Niewczas
Journal:  Clin Exp Nephrol       Date:  2013-11-12       Impact factor: 2.801

8.  [Insulin therapy of diabetes].

Authors:  Monika Lechleitner; Michael Roden; Raimund Weitgasser; Bernhard Ludvik; Peter Fasching; Friedrich Hoppichler; Alexandra Kautzky-Willer; Guntram Schernthaner; Rudolf Prager; Thomas C Wascher
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

9.  Current and future management of diabetic retinopathy: a personalized evidence-based approach.

Authors:  Ryan J Fante; Thomas W Gardner; Jeffrey M Sundstrom
Journal:  Diabetes Manag (Lond)       Date:  2013-11-01

Review 10.  Therapeutic approaches to diabetic nephropathy--beyond the RAS.

Authors:  Beatriz Fernandez-Fernandez; Alberto Ortiz; Carmen Gomez-Guerrero; Jesus Egido
Journal:  Nat Rev Nephrol       Date:  2014-05-06       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.